Get started
CORCEPT THERAPEUTICORCEPT THERAPEUTICORCEPT THERAPEUTI

CORCEPT THERAPEUTI

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

HTD chart


Full chart

HTD upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪6.12 B‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
79.535
Basic EPS (TTM)
1.133 CHF
Net income (FY)
‪126.91 M‬ CHF
Revenue (FY)
‪613.07 M‬ CHF
Shares float
‪93.80 M‬
Beta (1Y)
0.12

Employees


Employees (FY)
500
Change (1Y)
+148 +42.05%
Revenue / Employee (1Y)
‪1.23 M‬ CHF
Net income / Employee (1Y)
‪253.81 K‬ CHF

About Corcept Therapeutics Incorporated


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Joseph K. Belanoff
Website
corcept.com
Headquarters
Redwood City
Founded
1998
FIGI
BBG00LVD6673
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

HTD news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as HTD.

Frequently Asked Questions


The current price of HTD is 55.487 CHF — it has decreased by −26.51% in the past 24 hours. Watch CORCEPT THERAPEUTI stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange CORCEPT THERAPEUTI stocks are traded under the ticker HTD.
HTD stock has fallen by −26.51% compared to the previous week, the month change is a −26.51% fall, over the last year CORCEPT THERAPEUTI has showed a 151.61% increase.
We've gathered analysts' opinions on CORCEPT THERAPEUTI future price: according to them, HTD price has a max estimate of 119.22 CHF and a min estimate of 107.71 CHF. Watch HTD chart and read a more detailed CORCEPT THERAPEUTI stock forecast: see what analysts think of CORCEPT THERAPEUTI and suggest that you do with its stocks.
HTD reached its all-time high on Apr 1, 2025 with the price of 99.341 CHF, and its all-time low was 20.695 CHF and was reached on Nov 26, 2021. View more price dynamics on HTD chart.
See other stocks reaching their highest and lowest prices.
HTD stock is 36.07% volatile and has beta coefficient of 0.12. Track CORCEPT THERAPEUTI stock price on the chart and check out the list of the most volatile stocks — is CORCEPT THERAPEUTI there?
Today CORCEPT THERAPEUTI has the market capitalization of ‪6.02 B‬, it has increased by 1.17% over the last week.
Yes, you can track CORCEPT THERAPEUTI financials in yearly and quarterly reports right on TradingView.
CORCEPT THERAPEUTI is going to release the next earnings report on Jul 30, 2025. Keep track of upcoming events with our Earnings Calendar.
HTD earnings for the last quarter are 0.15 CHF per share, whereas the estimation was 0.13 CHF resulting in a 19.30% surprise. The estimated earnings for the next quarter are 0.15 CHF per share. See more details about CORCEPT THERAPEUTI earnings.
CORCEPT THERAPEUTI revenue for the last quarter amounts to ‪139.17 M‬ CHF, despite the estimated figure of ‪157.51 M‬ CHF. In the next quarter, revenue is expected to reach ‪161.65 M‬ CHF.
HTD net income for the last quarter is ‪17.96 M‬ CHF, while the quarter before that showed ‪27.60 M‬ CHF of net income which accounts for −34.93% change. Track more CORCEPT THERAPEUTI financial stats to get the full picture.
No, HTD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 14, 2025, the company has 500 employees. See our rating of the largest employees — is CORCEPT THERAPEUTI on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CORCEPT THERAPEUTI EBITDA is ‪99.63 M‬ CHF, and current EBITDA margin is 20.49%. See more stats in CORCEPT THERAPEUTI financial statements.
Like other stocks, HTD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CORCEPT THERAPEUTI stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CORCEPT THERAPEUTI technincal analysis shows the strong sell today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CORCEPT THERAPEUTI stock shows the strong buy signal. See more of CORCEPT THERAPEUTI technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.